NCT01011465

Brief Summary

Positive social relationships have consistently been associated with better health, although the neurobiological underpinnings of these observed effects remain largely unknown. The overall goal of the proposed work is to explore novel biological pathways that may explain how social relationships influence health. Recent theorizing suggests that the oxytocin system may underlie some of the observed beneficial effects. Four hypotheses will be examined:

  1. 1.Oxytocin ameliorates the deleterious neuroendocrine, cardiovascular, and subjective effects of stress.
  2. 2.Oxytocin and social support have similar and additive stress-buffering effects.
  3. 3.Effects of oxytocin are evident among younger and older adults.
  4. 4.Effects of oxytocin are stronger in women vs men.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
270

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2009

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

November 10, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 11, 2009

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
8 months until next milestone

Results Posted

Study results publicly available

November 26, 2012

Completed
Last Updated

November 26, 2012

Status Verified

October 1, 2012

Enrollment Period

3.2 years

First QC Date

November 10, 2009

Results QC Date

September 13, 2012

Last Update Submit

October 24, 2012

Conditions

Keywords

StressOxytocinSocial SupportResilience

Outcome Measures

Primary Outcomes (3)

  • Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure

    Systolic blood pressure (SBP)is connected with reaction to exposure to stress. Systolic blood pressure is collected at baseline and after nasal spray administration/directly before stress tasks; it represents anticipatory stress reaction. This measure represents the difference between baseline and pre-task systolic blood pressure values. A greater difference score represents an increase from baseline in systolic blood pressure during the pre-task, and so a larger difference score represents higher reactivity. A lower difference score, or negative difference score, indicates a lower increase, or even decrease, from baseline in systolic blood pressure during the pre-task and reflects less reactivity. Reactivity is associated with increased risk of developing hypertension. Range of baseline/pre-count differences in SBP: -11 to 37.7

    within 2 hours of treatment

  • Difference of Pre-count and Baseline Self-reported Negative Affect (Using Negative Sub-scale of Positive and Negative Affect Schedule (PANAS) Measure).

    Based on 20-item Positive and Negative Affect Schedule (PANAS) which comprises two mood scales, positive affect and negative affect. Each item is rated on a 5-point scale ranging from (1 = very slightly or not at all) to (5 = extremely) to indicate how the respondent felt at the moment the question was asked. Here, we've used the negative affect sub-scale which consists of the sum of the 10 negative affect items, with a possible range of 10 (least negative affect) to 50 (most negative affect). This score was measured at baseline (study range: 10 to 29) and directly before stress exposure (study range: 10 to 37), and the reported value is the difference between these two scores (range of differences: -13 to 26). It estimates negative affect due to anticipatory stress. The value is the difference between the pre-stress measure and baseline measure, therefore a larger number for the difference means a bigger increase in negative affect due to anticipatory stress, and is a worse outcome.

    2 hours

  • Speech Threat and Challenge

    Measure of threat and challenge calculated from observation of non-verbal behavioral cues during stress exposure. Threat (negative reaction) results when an individual does not feel that he or she has sufficient resources to complete a task or manage a difficult situation. Its reverse, challenge (positive reaction), occurs when an individual perceives that he or she has sufficient resources. Independent observers used videotapes of behavior during the stress tasks and rated participants on 7 point scales for 11 challenge-related behaviors (comfortable, confident, enthusiastic, clear, alert, high level of eye contact, etc), and for 8 threat-related behaviors (agitation, rigid posture, speech disfluency, etc). Challenge scores were averaged, and threat scores averaged then reverse-scored. The mean of challenge and reversed threat scores comprise the score used here. Range: 1.1 to 6.1, with higher scores representing more challenge orientation and reflecting a better outcome.

    2 hours

Study Arms (6)

Oxytocin

EXPERIMENTAL

One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol

Drug: intranasal oxytocinBehavioral: Social supportBehavioral: No Social Support

Placebo

PLACEBO COMPARATOR

The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray

Drug: PlaceboBehavioral: Social supportBehavioral: No Social Support

Social Support

EXPERIMENTAL

Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks

Drug: intranasal oxytocinDrug: PlaceboBehavioral: Social support

No Social Support

PLACEBO COMPARATOR

Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.

Drug: intranasal oxytocinDrug: PlaceboBehavioral: No Social Support

Female Gender

OTHER

Effects of oxytocin and social support are examined among women versus men

Drug: intranasal oxytocinDrug: PlaceboBehavioral: Social supportBehavioral: No Social Support

Male Gender

OTHER

Consider effects of oxytocin and social support in men versus women

Drug: intranasal oxytocinDrug: PlaceboBehavioral: Social supportBehavioral: No Social Support

Interventions

The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes

Also known as: Pitocin
Female GenderMale GenderNo Social SupportOxytocinSocial Support

Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes

Female GenderMale GenderNo Social SupportPlaceboSocial Support
Social supportBEHAVIORAL

Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.

Female GenderMale GenderOxytocinPlaceboSocial Support

Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.

Female GenderMale GenderNo Social SupportOxytocinPlacebo

Eligibility Criteria

Age22 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 22-65, BMI \< 30, healthy, English-speaking, 9th grade reading level.

You may not qualify if:

  • any known medical condition (including mental disorders) or on any type of medication
  • high levels of social anxiety
  • smokers
  • high rates of alcohol or drug use
  • pregnant or suspected pregnant
  • breastfeeding
  • blood pressures \> 140/90 mm Hg
  • subject does not have a close friend available to participate in the study with him/her

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Harvard School of Public Health

Boston, Massachusetts, 02115, United States

Location

Related Publications (2)

  • Kubzansky LD, Mendes WB, Appleton A, Block J, Adler GK. Protocol for an experimental investigation of the roles of oxytocin and social support in neuroendocrine, cardiovascular, and subjective responses to stress across age and gender. BMC Public Health. 2009 Dec 21;9:481. doi: 10.1186/1471-2458-9-481.

    PMID: 20025778BACKGROUND
  • Kubzansky LD, Mendes WB, Appleton AA, Block J, Adler GK. A heartfelt response: Oxytocin effects on response to social stress in men and women. Biol Psychol. 2012 Apr;90(1):1-9. doi: 10.1016/j.biopsycho.2012.02.010. Epub 2012 Feb 23.

MeSH Terms

Interventions

Oxytocin

Intervention Hierarchy (Ancestors)

Pituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Limitations and Caveats

Data collected earlier in the study is missing blood pressure data due to technical problems.

Results Point of Contact

Title
Dr. Laura Kubzansky
Organization
Harvard School of Public Health

Study Officials

  • Laura D Kubzansky, PhD

    Harvard School of Public Health (HSPH)

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

November 10, 2009

First Posted

November 11, 2009

Study Start

February 1, 2009

Primary Completion

April 1, 2012

Study Completion

April 1, 2012

Last Updated

November 26, 2012

Results First Posted

November 26, 2012

Record last verified: 2012-10

Locations